Insight Molecular Diagnostics (IMDX) Retained Earnings (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Retained Earnings for 6 consecutive years, with -$400.8 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 14.33% to -$400.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$400.8 million through Dec 2025, down 14.33% year-over-year, with the annual reading at -$400.8 million for FY2025, 14.33% down from the prior year.
- Retained Earnings hit -$400.8 million in Q4 2025 for Insight Molecular Diagnostics, down from $86000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $86000.0 in Q3 2025 to a low of -$400.8 million in Q4 2025.
- Historically, Retained Earnings has averaged -$198.3 million across 5 years, with a median of -$234.2 million in 2022.
- Biggest five-year swings in Retained Earnings: soared 100.03% in 2022 and later crashed 1379547.37% in 2023.
- Year by year, Retained Earnings stood at -$187.8 million in 2021, then soared by 100.02% to $39000.0 in 2022, then plummeted by 743371.79% to -$289.9 million in 2023, then decreased by 20.93% to -$350.5 million in 2024, then dropped by 14.33% to -$400.8 million in 2025.
- Business Quant data shows Retained Earnings for IMDX at -$400.8 million in Q4 2025, $86000.0 in Q3 2025, and -$367.0 million in Q2 2025.